Prescription drug cost barriers are increasingly causing people to divert from doctor-recommended treatment plans.

Most-favored-nation pricing is “founded on incorrect assumptions about where high out-of-pocket costs really come from and what it would mean for the US to adopt cost-effectiveness standards used by ...

Patent settlements accelerate the entry of generics and biosimilars, saving the health care system $422.9 billion and ...

Discover trends shaping the pharmaceutical sector. Get insights on rising prescription drug prices, supply chains, and growth ...

40% of generic demand in the US and 25% of all medicine in the UK. The domestic pharmaceutical industry includes a network of 3,000 drug companies and ~10,500 manufacturing units. India enjoys an ...

The recent dismissal of 13 FDA review staff eliminated precisely the kind of government spending that delivered the most bang ...

While the Trump administration’s threat of pharmaceutical import tariffs and most favored nation (MFN) drug pricing has ...

Pharmaceutical companies are obligated to follow regulations and are responsible for continuously monitoring the safety of their products and updating safety labels as new information becomes ...

The expiration of patents creates billion-dollar market opportunities for generic drug manufacturers. Healthcare providers and insurers show a growing preference for generic medications as ...

The availability of off-patent products enables generic manufacturers to offer cost-efficient ... expedite the approval process for generic drugs to support the market. The U.S. FDA and the ...

The litigation, specifically MDL 2724, alleges that Sandoz Inc. and other generic drug manufacturers conspired to fix the prices of generic drugs.